The Role of AI in Drug, Design and Synthesis of Target Molecule
Nagawade Harshada Vijay · Zenodo (CERN European Organization for Nuclear Research) · 2026
Artificial intelligence (AI) has emerged as a transformative technology in pharmaceutical research, revolutionizing traditional drug discovery paradigms. This report examines the integration of AI methodologies in drug design, molecular optimization, and synthesis planning. By leveraging machine learning algorithms, deep neural networks, and generative models, researchers can now predict molecular properties, design novel compounds, and plan synthetic routes with unprecedented efficiency. This paper reviews current AI applications, discusses key methodologies, presents case studies, and evaluates the challenges and future prospects of AI-driven drug discovery. Artificial intelligence (AI) has emerged as a transformative and disruptive force in pharmaceutical research, fundamentally reshaping traditional drug discovery and development paradigms. Conventional drug discovery is often characterized by long timelines, high costs, and low success rates, largely due to the complexity of biological systems and the trial-and-error nature of compound screening. The integration of AI technologies offers a powerful alternative by enabling data-driven decision-making, accelerating discovery processes, and reducing overall risk. This report examines the growing integration of AI methodologies across multiple stages of drug discovery, including target identification, drug design, molecular optimization, and synthesis planning. By leveraging advanced machine learning techniques, deep neural networks, and generative models, researchers can analyse vast and complex datasets that far exceed human analytical capacity. These models enable accurate prediction of molecular properties such as bioactivity, toxicity, solubility, and pharmacokinetics, allowing scientists to prioritize the most promising candidates early in the development pipeline. AI-driven generative models play a particularly critical role in the design of novel drug candidates. These models can generate new chemical structures with desired properties, explore previously uncharted regions of chemical space, and optimize molecular scaffolds through iterative learning. Additionally, reinforcement learning and graph-based neural networks have enhanced molecular optimization by refining compounds to improve efficacy while minimizing adverse effects. In parallel, AI-powered synthesis planning tools assist chemists by predicting feasible synthetic routes, estimating reaction outcomes, and reducing experimental workload in laboratory settings. This paper reviews current applications of AI in pharmaceutical research, highlighting key methodologies and algorithmic approaches that underpin modern AI-driven drug discovery. It presents representative case studies demonstrating successful implementation of AI in real-world drug development projects, including accelerated lead identification and repurposing of existing drugs. Furthermore, the report evaluates the challenges associated with AI adoption, such as data quality and availability, model interpretability, integration with experimental workflows, and regulatory considerations.